首页 / 配资查查

倍捷乐®纳入新国家医保药品目录,助力提升患者用药可及性

2026-11-16 · 富华优配

[1] YU K, CAO C, AN F, et al. Analysis and contrast of psoriasis disease burden trends in China and globally from 1990 to 2021[J]. Frontiers in Public Health, 2025, 13: 1541292. DO

[1] YU K, CAO C, AN F, et al. Analysis and contrast of psoriasis disease burden trends in China and globally from 1990 to 2021[J]. Frontiers in Public Health, 2025, 13: 1541292. DOI: 10.3389/fpubh.2025.1541292. [2] PHAN K, CHARLTON O, SMITH S D. Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta-analysis[J]. Biomedical Dermatology, 2020, 4: 2. DOI: 10.1186/s41702-019-0052-0.

[3] 黄烽,朱剑,王玉华,等. 强直性脊柱炎诊疗规范[J]. 中华内科杂志,2022,61(08):893-900.

[4] Davydova A, Kurochkina Y, Goncharova V, et al. The Interleukine-17 cytokine family: role in development and progression of spondyloarthritis, current and potential therapeutic inhibitors. Biomedicines. 2023;11(5):1328.

[5] Garrido-Cumbrera M, Bundy C, Navarro-Compán V, et al. Patient-Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey. Arthritis Care Res (Hoboken). 2021;73(12):1826-1833. doi:10.1002/acr.24426.

声明 未经授权,不得复制、转载或以其他方式使用本站内容。格隆汇及授权的第三方信息提供者竭力确保数据准确可靠,但不保证数据绝对正确。

违法与不良信息举报热线:0755-86533750-821 举报邮箱:service@gelonghui.com

富华优配风险提示财经资料
本文仅用于资料整理和学习交流,不构成投资建议,不承诺收益,也不替代个人风险判断。